Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01881048 · ClinicalTrials.gov registry record · Early Phase 1
Window of Opportunity Study Targeting the Inflammatory Milieu
A Early Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 42
- Enrollment target
NCT01881048 is a Early Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 42 participants.
The verdict
NCT01881048, a Early Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of two anti-inflammatory drugs, fish oil capsules and the COX-2 inhibitor celecoxib, on pregnancy associated breast cancer (PABC). Short-term intervention with anti-inflammatory medications will demonstrate a reduction in the inflammation and immune suppressive phenotype of PABC, and decreased metastatic potential in PABC. This unique window in breast cancer management serves as a valuable opportunity to obtain preliminary data on biomarkers and the alterations that occur when the system is troubled by a drug or other intervention which will be instrumental in designing future therapeutic or preventative strategies for larger clinical study.
Interventions
- DRUG Celecoxib
- DIETARY_SUPPLEMENT Omega-3 fatty acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2009-12-08 |
| Est. Completion | 2015-12-14 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01881048
The ClinicalTrials.gov registry entry for NCT01881048 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Celecoxib is the first listed.
NCT01881048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01881048 about?
NCT01881048 is a clinical study titled "Window of Opportunity Study Targeting the Inflammatory Milieu". The purpose of this study is to evaluate the effect of two anti-inflammatory drugs, fish oil capsules and the COX-2 inhibitor celecoxib, on pregnancy associated breast cancer (PABC). Short-term intervention with anti-inflammatory medications will demonstrate a reduction in the inflammation and immun...
What is the current status of trial NCT01881048?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 42 participants. The study started on 2009-12-08. Estimated completion is 2015-12-14.
What interventions are being tested in trial NCT01881048?
The interventions under investigation include: Celecoxib (DRUG), Omega-3 fatty acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01881048?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.